Breast cancer, a pervasive threat to women's health worldwide, demands precise molecular subtyping for effective treatment. But here's the challenge: traditional biopsies often fall short, leading to misclassification. Enter DCE-MRI radiomics, a game-changer in non-invasive prediction. This cutting-edge approach combines dynamic contrast-enhanced MRI with advanced analytics, offering a comprehensive view of tumor behavior. But here's where it gets controversial: while DCE-MRI radiomics shows immense promise, its clinical adoption faces hurdles like standardization and interpretability. And this is the part most people miss: the integration of multidimensional features—morphological, textural, and high-order—unlocks intricate tumor-pathway associations, paving the way for precision medicine. From predicting hormone receptor status to identifying triple-negative breast cancer, radiomics is revolutionizing diagnostics. Yet, challenges persist, from data heterogeneity to retrospective study biases. The future lies in radiogenomics, multimodal integration, and AI-driven interpretability, promising to bridge the gap between imaging and molecular insights. But here's the question: Can radiomics truly transform breast cancer management, or will technical bottlenecks and clinical validation hurdles slow its progress? The answer may lie in collaborative innovation and standardized workflows, ensuring radiomics fulfills its potential in the precision oncology era.
